Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting

Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced preclinical data from multiple chimeric antigen receptor T cell (CAR-T) programs in Poseida’s drug development pipeline.